NETLIST INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NETLIST INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $38.32M | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $5.54M | Mar 30, 2018 |
| FY2017 | Oct 1, 2016 | $2.59M | Mar 30, 2018 |
| FY2017 | Jul 2, 2016 | $6.93M | Mar 30, 2018 |
| FY2017 | Apr 2, 2016 | $4.60M | Mar 30, 2018 |
| FY2016 | Jan 2, 2016 | $2.85M | Mar 31, 2017 |
| FY2016 | Sep 26, 2015 | $1.62M | Mar 31, 2017 |
| FY2016 | Jun 27, 2015 | $1.43M | Mar 31, 2017 |
| FY2016 | Mar 28, 2015 | $2.11M | Mar 31, 2017 |
| FY2015 | Dec 27, 2014 | $2.52M | Mar 4, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $11.44M | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | $2.88M | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | $2.39M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $11.89M | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | $48.90M | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | $6.73M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $2.57M | Mar 1, 2022 |
| FY2018 | Dec 29, 2018 | $854.0K | Mar 22, 2019 |
| FY2018 | Sep 29, 2018 | $586.0K | Mar 22, 2019 |
| FY2018 | Jun 30, 2018 | $482.0K | Mar 22, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($24.82M) | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | ($53.87M) | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | ($60.40M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($33.37M) | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | $4.83M | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | ($7.27M) | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | ($12.45M) | Mar 1, 2022 |
| FY2018 | Dec 29, 2018 | ($4.39M) | Mar 22, 2019 |
| FY2018 | Sep 29, 2018 | ($4.64M) | Mar 22, 2019 |
| FY2018 | Jun 30, 2018 | ($3.42M) | Mar 22, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($25.51M) | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | ($55.23M) | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | ($61.76M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($33.50M) | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | $11.38M | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | ($6.84M) | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | ($11.49M) | Mar 1, 2022 |
| FY2018 | Dec 29, 2018 | ($4.11M) | Mar 22, 2019 |
| FY2018 | Sep 29, 2018 | ($4.45M) | Mar 22, 2019 |
| FY2018 | Jun 30, 2018 | ($3.27M) | Mar 22, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $3.50M | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | $8.06M | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | $9.16M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $10.62M | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | $7.24M | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | $2.95M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $2.38M | Mar 1, 2022 |
| FY2018 | Dec 29, 2018 | $573.0K | Mar 22, 2019 |
| FY2018 | Sep 29, 2018 | $535.0K | Mar 22, 2019 |
| FY2018 | Jun 30, 2018 | $783.0K | Mar 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $13.22M | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | $12.09M | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | $12.41M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $14.35M | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | $10.78M | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | $8.25M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $7.55M | Mar 1, 2022 |
| FY2018 | Dec 29, 2018 | $1.84M | Mar 22, 2019 |
| FY2018 | Sep 29, 2018 | $1.75M | Mar 22, 2019 |
| FY2018 | Jun 30, 2018 | $1.59M | Mar 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($14.74M) | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | ($34.59M) | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | ($41.60M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($15.00M) | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | $6.01M | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | ($8.13M) | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | ($11.49M) | Mar 1, 2022 |
| FY2019 | Dec 29, 2018 | ($10.57M) | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | ($11.35M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($20.79M) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $42.0K | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | $71.0K | Mar 19, 2026 |
| FY2023 | Dec 31, 2022 | $467.0K | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | $520.0K | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | $43.0K | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $83.0K | Mar 1, 2022 |
| FY2019 | Dec 29, 2018 | $74.0K | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $94.0K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $346.0K | Mar 30, 2018 |
| FY2016 | Jan 2, 2016 | $366.0K | Mar 31, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $49.48M | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | $41.84M | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | $72.80M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $67.32M | Feb 23, 2024 |
| FY2022 | Jan 1, 2022 | $91.18M | Feb 28, 2023 |
| FY2021 | Jan 2, 2021 | $25.27M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $22.14M | Mar 26, 2021 |
| FY2019 | Dec 29, 2018 | $24.87M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $18.79M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $19.97M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $54.68M | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | $47.89M | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | $49.04M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $40.09M | Feb 23, 2024 |
| FY2022 | Jan 1, 2022 | $37.13M | Feb 28, 2023 |
| FY2021 | Jan 2, 2021 | $27.89M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $30.50M | Mar 26, 2021 |
| FY2019 | Dec 29, 2018 | $30.54M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $24.12M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $20.50M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($5.20M) | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | ($6.05M) | Mar 19, 2026 |
| FY2025 | Dec 30, 2023 | $23.76M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $27.24M | Mar 28, 2025 |
| FY2023 | Jan 1, 2022 | $54.04M | Feb 23, 2024 |
| FY2023 | Jan 2, 2021 | ($2.62M) | Feb 23, 2024 |
| FY2022 | Dec 28, 2019 | ($8.36M) | Feb 28, 2023 |
| FY2021 | Dec 29, 2018 | ($5.67M) | Mar 1, 2022 |
| FY2019 | Dec 30, 2017 | ($5.33M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | ($529.0K) | Mar 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($362.51M) | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | ($337.69M) | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | ($283.82M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($223.43M) | Feb 23, 2024 |
| FY2022 | Jan 1, 2022 | ($190.06M) | Feb 28, 2023 |
| FY2021 | Jan 2, 2021 | ($194.89M) | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | ($187.62M) | Mar 26, 2021 |
| FY2019 | Dec 29, 2018 | ($175.17M) | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | ($158.05M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($144.63M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $31.78M | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | $22.51M | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | $40.45M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $25.01M | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | $47.68M | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | $13.33M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $8.97M | Mar 1, 2022 |
| FY2019 | Dec 29, 2018 | $14.80M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $6.72M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $9.48M | Mar 30, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jan 2, 2021 | $17.43M | Mar 26, 2021 |
| FY2019 | Dec 28, 2019 | $16.65M | Mar 10, 2020 |
| FY2018 | Dec 29, 2018 | $18.64M | Mar 22, 2019 |
| FY2017 | Dec 30, 2017 | $15.63M | Mar 30, 2018 |
| FY2016 | Dec 31, 2016 | $15.49M | Mar 31, 2017 |
| FY2014 | Dec 27, 2014 | $5.84M | Mar 27, 2015 |
| FY2013 | Dec 28, 2013 | $6.11M | Mar 18, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | 0 | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | 0 | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | 0 | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 23, 2024 |
| FY2023 | Jan 1, 2022 | 0 | Feb 23, 2024 |
| FY2022 | Jan 2, 2021 | 0 | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | 0 | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 307.34M | Mar 19, 2026 |
| FY2025 | Dec 28, 2024 | 271.99M | Mar 19, 2026 |
| FY2024 | Dec 30, 2023 | 253.59M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 232.56M | Feb 23, 2024 |
| FY2022 | Jan 1, 2022 | 230.11M | Feb 28, 2023 |
| FY2021 | Jan 2, 2021 | 195.98M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | 169.54M | Mar 26, 2021 |
| FY2019 | Dec 29, 2018 | 139.28M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | 79.31M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 61.65M | Mar 30, 2018 |